Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE randomized clinical trial

Rajesh Thomas, Edward T.H. Fysh, Nicola A. Smith, Pyng Lee, Benjamin C.H. Kwan, Elaine Yap, Fiona C. Horwood, Francesco Piccolo, David C.L. Lam, Luke A. Garske, Ranjan Shrestha, Christopher Kosky, Catherine A. Read, Kevin Murray, Y. C.Gary Lee

Research output: Contribution to journalArticle

52 Citations (Scopus)
331 Downloads (Pure)

Abstract

IMPORTANCE: Indwelling pleural catheter and talc pleurodesis are established treatments for malignant pleural effusions among patients with poor prognosis. OBJECTIVE: To determine whether indwelling pleural catheters are more effective than talc pleurodesis in reducing total hospitalization days in the remaining lifespan of patients with malignant pleural effusion. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized clinical trial included participants recruited from 9 centers in Australia, New Zealand, Singapore, and Hong Kong between July 2012 and October 2014; they were followed up for 12 months (study end date: October 16, 2015). Patients (n = 146) with symptomatic malignant pleural effusion who had not undergone indwelling pleural catheter or pleurodesis treatment were included. INTERVENTIONS: Participants were randomized (1:1) to indwelling pleural catheter (n = 74) or talc pleurodesis (n = 72), minimized by malignancy (mesothelioma vs others) and trapped lung (vs not), and stratified by region (Australia vs Asia). MAIN OUTCOMES AND MEASURES: The primary end point was the total number of days spent in hospital from procedure to death or to 12 months. Secondary outcomes included further pleural interventions, patient-reported breathlessness, quality-of-life measures, and adverse events. RESULTS: Among 146 randomized patients (median age, 70.5 years; 56.2% male), 2 were excluded. The indwelling pleural catheter group spent significantly fewer days in hospital than the pleurodesis group. The reduction was mainly in effusion-related hospitalization days. Fewer patients randomized to indwelling pleural catheter required further ipsilateral invasive pleural drainages. There were no significant between-group differences in improvements in breathlessness or quality of life. Adverse events occurred in both groups: 30 events in 22 catheter patients and 23 events in 13 talc pleurodesis patients. (Table Presented). CONCLUSIONS AND RELEVANCE: Among patients with malignant pleural effusion, treatment with an indwelling pleural catheter vs talc pleurodesis resulted in fewer hospitalization days from treatment to death, but the magnitude of the difference is of uncertain clinical importance. These findings may help inform patient choice of management for pleural effusion. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12611000567921.

Original languageEnglish
Pages (from-to)1903-1912
Number of pages10
JournalJAMA - Journal of the American Medical Association
Volume318
Issue number19
DOIs
Publication statusPublished - 21 Nov 2017

Fingerprint

Pleurodesis
Malignant Pleural Effusion
Talc
Indwelling Catheters
Hospitalization
Randomized Controlled Trials
Dyspnea
Quality of Life
Singapore
Mesothelioma
Hong Kong
Pleural Effusion
Therapeutics
New Zealand
Drainage
Catheters
Outcome Assessment (Health Care)

Cite this

Thomas, Rajesh ; Fysh, Edward T.H. ; Smith, Nicola A. ; Lee, Pyng ; Kwan, Benjamin C.H. ; Yap, Elaine ; Horwood, Fiona C. ; Piccolo, Francesco ; Lam, David C.L. ; Garske, Luke A. ; Shrestha, Ranjan ; Kosky, Christopher ; Read, Catherine A. ; Murray, Kevin ; Lee, Y. C.Gary. / Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion : The AMPLE randomized clinical trial. In: JAMA - Journal of the American Medical Association. 2017 ; Vol. 318, No. 19. pp. 1903-1912.
@article{e58c929dd5c44656abfa978fc7fe3125,
title = "Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE randomized clinical trial",
abstract = "IMPORTANCE: Indwelling pleural catheter and talc pleurodesis are established treatments for malignant pleural effusions among patients with poor prognosis. OBJECTIVE: To determine whether indwelling pleural catheters are more effective than talc pleurodesis in reducing total hospitalization days in the remaining lifespan of patients with malignant pleural effusion. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized clinical trial included participants recruited from 9 centers in Australia, New Zealand, Singapore, and Hong Kong between July 2012 and October 2014; they were followed up for 12 months (study end date: October 16, 2015). Patients (n = 146) with symptomatic malignant pleural effusion who had not undergone indwelling pleural catheter or pleurodesis treatment were included. INTERVENTIONS: Participants were randomized (1:1) to indwelling pleural catheter (n = 74) or talc pleurodesis (n = 72), minimized by malignancy (mesothelioma vs others) and trapped lung (vs not), and stratified by region (Australia vs Asia). MAIN OUTCOMES AND MEASURES: The primary end point was the total number of days spent in hospital from procedure to death or to 12 months. Secondary outcomes included further pleural interventions, patient-reported breathlessness, quality-of-life measures, and adverse events. RESULTS: Among 146 randomized patients (median age, 70.5 years; 56.2{\%} male), 2 were excluded. The indwelling pleural catheter group spent significantly fewer days in hospital than the pleurodesis group. The reduction was mainly in effusion-related hospitalization days. Fewer patients randomized to indwelling pleural catheter required further ipsilateral invasive pleural drainages. There were no significant between-group differences in improvements in breathlessness or quality of life. Adverse events occurred in both groups: 30 events in 22 catheter patients and 23 events in 13 talc pleurodesis patients. (Table Presented). CONCLUSIONS AND RELEVANCE: Among patients with malignant pleural effusion, treatment with an indwelling pleural catheter vs talc pleurodesis resulted in fewer hospitalization days from treatment to death, but the magnitude of the difference is of uncertain clinical importance. These findings may help inform patient choice of management for pleural effusion. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12611000567921.",
author = "Rajesh Thomas and Fysh, {Edward T.H.} and Smith, {Nicola A.} and Pyng Lee and Kwan, {Benjamin C.H.} and Elaine Yap and Horwood, {Fiona C.} and Francesco Piccolo and Lam, {David C.L.} and Garske, {Luke A.} and Ranjan Shrestha and Christopher Kosky and Read, {Catherine A.} and Kevin Murray and Lee, {Y. C.Gary}",
year = "2017",
month = "11",
day = "21",
doi = "10.1001/jama.2017.17426",
language = "English",
volume = "318",
pages = "1903--1912",
journal = "JAMA: The Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "19",

}

Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion : The AMPLE randomized clinical trial. / Thomas, Rajesh; Fysh, Edward T.H.; Smith, Nicola A.; Lee, Pyng; Kwan, Benjamin C.H.; Yap, Elaine; Horwood, Fiona C.; Piccolo, Francesco; Lam, David C.L.; Garske, Luke A.; Shrestha, Ranjan; Kosky, Christopher; Read, Catherine A.; Murray, Kevin; Lee, Y. C.Gary.

In: JAMA - Journal of the American Medical Association, Vol. 318, No. 19, 21.11.2017, p. 1903-1912.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion

T2 - The AMPLE randomized clinical trial

AU - Thomas, Rajesh

AU - Fysh, Edward T.H.

AU - Smith, Nicola A.

AU - Lee, Pyng

AU - Kwan, Benjamin C.H.

AU - Yap, Elaine

AU - Horwood, Fiona C.

AU - Piccolo, Francesco

AU - Lam, David C.L.

AU - Garske, Luke A.

AU - Shrestha, Ranjan

AU - Kosky, Christopher

AU - Read, Catherine A.

AU - Murray, Kevin

AU - Lee, Y. C.Gary

PY - 2017/11/21

Y1 - 2017/11/21

N2 - IMPORTANCE: Indwelling pleural catheter and talc pleurodesis are established treatments for malignant pleural effusions among patients with poor prognosis. OBJECTIVE: To determine whether indwelling pleural catheters are more effective than talc pleurodesis in reducing total hospitalization days in the remaining lifespan of patients with malignant pleural effusion. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized clinical trial included participants recruited from 9 centers in Australia, New Zealand, Singapore, and Hong Kong between July 2012 and October 2014; they were followed up for 12 months (study end date: October 16, 2015). Patients (n = 146) with symptomatic malignant pleural effusion who had not undergone indwelling pleural catheter or pleurodesis treatment were included. INTERVENTIONS: Participants were randomized (1:1) to indwelling pleural catheter (n = 74) or talc pleurodesis (n = 72), minimized by malignancy (mesothelioma vs others) and trapped lung (vs not), and stratified by region (Australia vs Asia). MAIN OUTCOMES AND MEASURES: The primary end point was the total number of days spent in hospital from procedure to death or to 12 months. Secondary outcomes included further pleural interventions, patient-reported breathlessness, quality-of-life measures, and adverse events. RESULTS: Among 146 randomized patients (median age, 70.5 years; 56.2% male), 2 were excluded. The indwelling pleural catheter group spent significantly fewer days in hospital than the pleurodesis group. The reduction was mainly in effusion-related hospitalization days. Fewer patients randomized to indwelling pleural catheter required further ipsilateral invasive pleural drainages. There were no significant between-group differences in improvements in breathlessness or quality of life. Adverse events occurred in both groups: 30 events in 22 catheter patients and 23 events in 13 talc pleurodesis patients. (Table Presented). CONCLUSIONS AND RELEVANCE: Among patients with malignant pleural effusion, treatment with an indwelling pleural catheter vs talc pleurodesis resulted in fewer hospitalization days from treatment to death, but the magnitude of the difference is of uncertain clinical importance. These findings may help inform patient choice of management for pleural effusion. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12611000567921.

AB - IMPORTANCE: Indwelling pleural catheter and talc pleurodesis are established treatments for malignant pleural effusions among patients with poor prognosis. OBJECTIVE: To determine whether indwelling pleural catheters are more effective than talc pleurodesis in reducing total hospitalization days in the remaining lifespan of patients with malignant pleural effusion. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized clinical trial included participants recruited from 9 centers in Australia, New Zealand, Singapore, and Hong Kong between July 2012 and October 2014; they were followed up for 12 months (study end date: October 16, 2015). Patients (n = 146) with symptomatic malignant pleural effusion who had not undergone indwelling pleural catheter or pleurodesis treatment were included. INTERVENTIONS: Participants were randomized (1:1) to indwelling pleural catheter (n = 74) or talc pleurodesis (n = 72), minimized by malignancy (mesothelioma vs others) and trapped lung (vs not), and stratified by region (Australia vs Asia). MAIN OUTCOMES AND MEASURES: The primary end point was the total number of days spent in hospital from procedure to death or to 12 months. Secondary outcomes included further pleural interventions, patient-reported breathlessness, quality-of-life measures, and adverse events. RESULTS: Among 146 randomized patients (median age, 70.5 years; 56.2% male), 2 were excluded. The indwelling pleural catheter group spent significantly fewer days in hospital than the pleurodesis group. The reduction was mainly in effusion-related hospitalization days. Fewer patients randomized to indwelling pleural catheter required further ipsilateral invasive pleural drainages. There were no significant between-group differences in improvements in breathlessness or quality of life. Adverse events occurred in both groups: 30 events in 22 catheter patients and 23 events in 13 talc pleurodesis patients. (Table Presented). CONCLUSIONS AND RELEVANCE: Among patients with malignant pleural effusion, treatment with an indwelling pleural catheter vs talc pleurodesis resulted in fewer hospitalization days from treatment to death, but the magnitude of the difference is of uncertain clinical importance. These findings may help inform patient choice of management for pleural effusion. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12611000567921.

UR - http://www.scopus.com/inward/record.url?scp=85036586035&partnerID=8YFLogxK

U2 - 10.1001/jama.2017.17426

DO - 10.1001/jama.2017.17426

M3 - Article

VL - 318

SP - 1903

EP - 1912

JO - JAMA: The Journal of the American Medical Association

JF - JAMA: The Journal of the American Medical Association

SN - 0098-7484

IS - 19

ER -